Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Fr Brunsvig, Paal ^a   Andersen, Anders ^a   Aamdal, Steinar ^a,b   Kristensen, Vessela ^a   Olsen, Harald ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; PACLITAXEL; ANTINEOPLASTIC AGENT; OROSOMUCOID; TAXOID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG INTERACTION; DRUG USE; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFECTION; LOW DRUG DOSE; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; PARESTHESIA; PNEUMONIA; QUANTITATIVE ANALYSIS; RADIOSENSITIVITY; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; LUNG TUMOR; MIDDLE AGED; RADIOTHERAPY; REPRODUCIBILITY;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OROSOMUCOID; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; TAXOIDS;

EID: 38049155886     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-197     Document Type: Article

References (29)

1. Chu Q Vincent M Logan D Mackay JA Evans WK Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline Lung Cancer 2005, 50:355-374. 10.1016/ j.lungcan.2005.06.010 16139391
2. Hainsworth JD Burris HA III Litchy S Morrissey LH Barton JH Bradof JE Greco FA Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial Cancer 2000, 89:328-333. 10.1002/ 1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F 10918162
3. Schuette W Nagel S Blankenburg T Lautenschlaeger C Hans K Schmidt EW Dittrich I Schweisfurth H von Weikersthal LF Raghavachar A Reissig A Serke M Phase III Study of Second-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel J Clin Oncol 2005, 23:8389-8395. 10.1200/JCO.2005.02.3739 16293869
4. Gueritte-Voegelein F Guenard D Lavelle F Le Goff MT Mangatal L Potier P Relationships between the structure of taxol analogues and their antimitotic activity J Med Chem 1991, 34:992-998. 10.1021/jm00107a017 1672159
5. Ringel I Horwitz SB Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol J Natl Cancer Inst 1991, 83:288-291. 10.1093/jnci/ 83.4.288 1671606
6. ten Tije AJ Verweij J Carducci MA Graveland W Rogers T Pronk T Verbruggen MP Dawkins F Baker SD Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly J Clin Oncol 2005, 23:1070-1077. 10.1200/JCO.2005.03.082 15718305
7. Bruno R Hille D Riva A Vivier N ten Bokkel H van Oosterom AT Kaye SB Verweij J Fossella FV Valero V Rigas JR Seidman AD Chevallier B Fumoleau P Burris HA Ravdin PM Sheiner LB Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer J Clin Oncol 1998, 16:187-196. 9440742
8. Baker SD Li J ten Tije AJ Figg WD Graveland W Verweij J Sparreboom A Relationship of systemic exposure to unbound docetaxel and neutropenia Clinical Pharmacology & Therapeutics 2005, 77:43-53.
9. Clarke SJ Rivory LP Clinical pharmacokinetics of docetaxel Clin Pharmacokinet 1999, 36:99-114. 10.2165/00003088-199936020-00002 10092957
10. Pradier O Rave-Frank M Lehmann J Lucke E Boghun O Hess CF Schmidberger H Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki) Int J Cancer 2001, 91:840-845. 10.1002/ 1097-0215(200002)9999:9999<::AID-IJC1142>3.0.CO;2-U 11275989
11. Mason KA Hunter NR Milas M Abbruzzese JL Milas L Docetaxel enhances tumor radioresponse in vivo Clin Cancer Res 1997, 3:2431-2438. 9815644
12. Scagliotti GV Douillard JY Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer Lung Cancer 2004, 46:S13-21. 10.1016/S0169-5002(04)80037-0 15698527
13. Brunsvig PF Hatlevoll R Berg R Lauvvang G Owre K Wang M Aamdal S Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: A Phase I/II study with 5 years' follow-up Lung Cancer 2005, 50:97-105. 10.1016/j.lungcan.2005.05.010 16005105
14. Mauer AM Masters GA Haraf DJ Hoffman PC Watson SM Golomb HM Vokes EE Phase I study of docetaxel with concomitant thoracic radiation therapy J Clin Oncol 1998, 16:159-164. 9440738
15. Andersen A Warren D Brunsvig P Aamdal S Kristensen G Olsen H High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection BMC Clinical Pharmacology 2006, 6:2. 1382254 16412237 10.1186/1472-6904-6-2
16. Gurney H Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative J Clin Oncol 1996, 14:2590-2611. 8823340
17. Baker SD Sparreboom A Verweij J Clinical pharmacokinetics of docetaxel: recent developments Clin Pharmacokinet 2006, 45:235-252. 10.2165/ 00003088-200645030-00002 16509758
18. Edvardsen H Brunsvig P Tsalenko A Andersen A Ben-Dor A Syvanen AC Yakhini Z Børresen-Dale AL Olsen H Aamdal S Kristensen VN SNPs predictors of Docetaxel clearence Human Genome Meeting HGM 2006 2006:P 195.
19. Baker SD Zhao M Lee CKK Verweij J Zabelina Y Brahmer JR Wolff AC Sparreboom A Carducci MA Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel Clin Cancer Res 2004, 10:1976-1983. 10.1158/ 1078-0432.CCR-0842-03 15041715
20. Engels FK Sparreboom A Mathot RA Verweij J Potential for improvement of docetaxel-based chemotherapy: A pharmacological review Br J Cancer 2005, 93:173-177. 10.1038/sj.bjc.6602698 16012521
21. Baker SD van Schaik RH Rivory LP ten Tije AJ Dinh K Graveland WJ Schenk PW Charles KA Clarke SJ Carducci MA McGuire WP Dawkins F Gelderblom H Verweij J Sparreboom A Factors affecting cytochrome P-450 3A activity in cancer patients Clin Cancer Res 2004, 10:8341-8350. 10.1158/ 1078-0432.CCR-04-1371 15623611
22. Bruno R Olivares R Berille J Chaikin P Vivier N Hammershaimb L Rhodes GR Rigas JR {alpha}-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel Clin Cancer Res 2003, 9:1077-1082. 12631610
23. Scagliotti GV Szczesna A Ramlau R Cardenal F Mattson K Van ZN Price A Lebeau B Debus J Manegold C Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer Br J Cancer 2006, 94:1375-1382. 10.1038/sj.bjc.6603115 16641904
24. Choy H Taxanes in combined modality therapy for solid tumors Crit Rev Oncol Hematol 2001, 37:237-247. 10.1016/S1040-8428(00)00112-8 11248579
25. Balcer-Kubiczek EK Attarpour M Jiang J Kennedy AS Suntharalingam M Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells Chemotherapy 2006, 52:231-240. 10.1159/000094869 16899972
26. Mori T Kinoshita Y Watanabe A Yamaguchi T Hosokawa K Honjo H Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro Cancer Chemother Pharmacol 2006, 58:665-672. 10.1007/s00280-006-0209-6 16534615
27. Creane M Seymour CB Colucci S Mothersill C Radiobiological effects of docetaxel (Taxotere): A potential radiation sensitizer Int J Radiat Biol 1999, 75:731-737. 10.1080/095530099140078 10405003
28. Gustafson DL Long ME Zirrolli JA Duncan MW Holden SN Pierson AS Eckhardt SG Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay Cancer Chemother Pharmacol 2003, 52:159-166. 10.1007/ s00280-003-0622-z 12759775
29. Huber RM Flentje M Schmidt M Pollinger B Gosse H Willner J Ulm K Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group J Clin Oncol 2006, 24:4397-4404. 10.1200/JCO.2005.05.4163 16983107